These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27206758)

  • 21. Comparison of fractional erbium:YAG laser-assisted tranexamic acid delivery alone and in combination with oral tranexamic acid in melasma.
    Botsali A; Esme P; Erbil H; Caliskan E
    Lasers Med Sci; 2022 Sep; 37(7):2823-2830. PubMed ID: 35347552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral tranexamic acid with a triple combination cream versus oral tranexamic acid monotherapy in the treatment of severe melasma.
    Martinez-Rico JC; Chavez-Alvarez S; Herz-Ruelas ME; Sosa-Colunga SA; Ocampo-Candiani J; Suro-Santos Y; Vazquez Martinez O
    J Cosmet Dermatol; 2022 Aug; 21(8):3451-3457. PubMed ID: 35340120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histological changes in facial melasma after treatment with triple combination cream with or without oral tranexamic acid and/or microneedling: A randomised clinical trial.
    Cassiano DP; Espósito ACC; Hassun KM; Lima MMDA; Lima EVA; Miot LDB; Miot HA; Bagatin E
    Indian J Dermatol Venereol Leprol; 2022; 88(6):761-770. PubMed ID: 35389028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tranexamic acid: an important adjuvant in the treatment of melasma.
    Tse TW; Hui E
    J Cosmet Dermatol; 2013 Mar; 12(1):57-66. PubMed ID: 23438143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and possible mechanisms of topical tranexamic acid in melasma.
    Kim SJ; Park JY; Shibata T; Fujiwara R; Kang HY
    Clin Exp Dermatol; 2016 Jul; 41(5):480-5. PubMed ID: 27135282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of melasma using tranexamic acid: what's known and what's next.
    Sheu SL
    Cutis; 2018 Feb; 101(2):E7-E8. PubMed ID: 29554171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma.
    Sahu PJ; Singh AL; Kulkarni S; Madke B; Saoji V; Jawade S
    J Cosmet Dermatol; 2020 Jun; 19(6):1456-1462. PubMed ID: 32346962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, open-label, comparative study of oral tranexamic acid and tranexamic acid microinjections in patients with melasma.
    Khurana VK; Misri RR; Agarwal S; Thole AV; Kumar S; Anand T
    Indian J Dermatol Venereol Leprol; 2019; 85(1):39-43. PubMed ID: 30333359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of tranexamic acid in the treatment of melasma.
    Bagherani N
    Dermatol Ther; 2015; 28(4):265. PubMed ID: 25649261
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral Tranexamic Acid for the Treatment of Melasma: A Review.
    Bala HR; Lee S; Wong C; Pandya AG; Rodrigues M
    Dermatol Surg; 2018 Jun; 44(6):814-825. PubMed ID: 29677015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evaluation of efficacy and tolerability of cysteamine 5% cream in comparison with tranexamic acid mesotherapy in subjects with melasma: a single-blind, randomized clinical trial study.
    Karrabi M; Mansournia MA; Sharestanaki E; Abdollahnejad Y; Sahebkar M
    Arch Dermatol Res; 2021 Sep; 313(7):539-547. PubMed ID: 32879998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of topical tranexamic acid (liposomal or lotion with microneedling) versus conventional hydroquinone in the treatment of melasma.
    Xing X; Chen L; Xu Z; Jin S; Zhang C; Xiang L
    J Cosmet Dermatol; 2020 Dec; 19(12):3238-3244. PubMed ID: 33091202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fractional erbium:YAG laser (2940 nm) plus topical hydroquinone compared to intradermal tranexamic acid plus topical hydroquinone for the treatment of refractory melasma: a randomized controlled trial.
    Mokhtari F; Bahrami B; Faghihi G; Asilian A; Iraji F
    J Dermatolog Treat; 2022 Aug; 33(5):2475-2481. PubMed ID: 34387527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A split face comparative study between intradermal tranexamic acid and Erbium-YAG laser in treatment of melasma.
    Otb S; Shaarawy E; Sadek A; Abdallah N; Agamia N; Soliman M; Tawfik AA
    J Dermatolog Treat; 2022 Feb; 33(1):555-559. PubMed ID: 32420770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study between oral tranexamic acid versus oral tranexamic acid and Q-switched Nd-YAG laser in melasma treatment: a clinical and dermoscopic evaluation.
    Agamia N; Apalla Z; Salem W; Abdallah W
    J Dermatolog Treat; 2021 Nov; 32(7):819-826. PubMed ID: 31908179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of oral tranexamic acid as an adjuvant in Indian patients with melasma: a prospective, interventional, single-centre, triple-blind, randomized, placebo-control, parallel group study.
    Minni K; Poojary S
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2636-2644. PubMed ID: 32567734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma.
    Laothaworn V; Juntongjin P
    J Cosmet Laser Ther; 2018 Oct; 20(6):320-325. PubMed ID: 29461121
    [No Abstract]   [Full Text] [Related]  

  • 38. Liposomal azelaic acid 20% cream vs hydroquinone 4% cream as adjuvant to oral tranexamic acid in melasma: a comparative study.
    Akl EM
    J Dermatolog Treat; 2022 Jun; 33(4):2008-2013. PubMed ID: 33823725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: A split-face comparative clinical, histopathological, and antera 3D camera study.
    El-Husseiny R; Rakha N; Sallam M
    Dermatol Ther; 2020 Nov; 33(6):e14240. PubMed ID: 32856757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescribing practices of tranexamic acid for melasma: Delphi consensus from the Pigmentary Disorders Society.
    Sarkar R; Narayan R V; Vinay K; Lakhani R; Sinha S; Mysore V; Sendhil Kumaran M; Bhalla M; Das A; Swarnkar B; Mohan Thappa D; Podder I; Ojha Sharma R; Kumar Somani V; Barua S; Jagadeesan S; Dogra S
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):41-45. PubMed ID: 37609738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.